Enabling On-Demand Therapies RARECast podcast

Artwork

Health Industry Business Health Care Rare Disease RARECast Health and Well-Being

Indhold leveret af RARECast. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af RARECast eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

RARECast « »
Enabling On-Demand Therapies

3M ago 39:56

Del

MP3•Episode hjem

Indhold leveret af RARECast. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af RARECast eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

Earlier this year, the company gained attention when it reported that developed a customized antisense oligonucleotide to treat a boy with an ultra-rare neurodevelopmental disorder in a year’s time. The company is leveraging AI to develop oligonucleotide medicines on demand. We spoke to Chris Hart, co-founder, president and CEO of Creyon Bio; about the proof-of-concept achieved with its recent N-of-1 therapy, the business model for Creyon, and the potential for its approach to reduce the time and cost of drug development.

… continue reading

519 episoder

#Health Industry #Business #Health Care #Rare Disease #RARECast #Health and Well-Being

Artwork

Enabling On-Demand Therapies

28 subscribers

published 3M ago

Del

MP3•Episode hjem

Indhold leveret af RARECast. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af RARECast eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

Earlier this year, the company gained attention when it reported that developed a customized antisense oligonucleotide to treat a boy with an ultra-rare neurodevelopmental disorder in a year’s time. The company is leveraging AI to develop oligonucleotide medicines on demand. We spoke to Chris Hart, co-founder, president and CEO of Creyon Bio; about the proof-of-concept achieved with its recent N-of-1 therapy, the business model for Creyon, and the potential for its approach to reduce the time and cost of drug development.

… continue reading

519 episoder

#Health Industry #Business #Health Care #Rare Disease #RARECast #Health and Well-Being

Alle episoder

×

Velkommen til Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

Lyt til 500+ emner